Non-amyloid fibrillary glomerulopathy

Summary

Non-amyloid fibrillary glomerulopathy (MONDO:0019990) is a disease and 5 clinical trials. Top therapeutic interventions include corticotropin and rituximab. A subtype of immunotactoid or fibrillary glomerulopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-amyloid fibrillary glomerulopathy
Mondo ID	MONDO:0019990
Orphanet	97566
SNOMED CT	718192000
UMLS	C4273674
MedGen	907201
GARD	0012740
NORD	2024
Is cancer (heuristic)	no

Also known as: Congo red-negative amyloidosis-like glomerulopathy · fibrillary glomerulonephritis · Fibrillary Glomerulonephritis  · non-amyloid fibrillary glomerulonephritis

Disease family

This is a subtype of immunotactoid or fibrillary glomerulopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › glomerular disorder › immunotactoid or fibrillary glomerulopathy › non-amyloid fibrillary glomerulopathy

Related subtypes (1): immunotactoid glomerulopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	2
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05546047	PHASE4	UNKNOWN	A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
NCT06680349	PHASE4	COMPLETED	Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
NCT06295770	PHASE2	RECRUITING	Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NCT02197767	PHASE2	COMPLETED	Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
NCT06065852	Not specified	RECRUITING	National Registry of Rare Kidney Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CORTICOTROPIN	4	1
RITUXIMAB	4	1